{"id":"endostar-continuous-intravenous-infusion","safety":{"commonSideEffects":[{"rate":null,"effect":"Hypertension"},{"rate":null,"effect":"Proteinuria"},{"rate":null,"effect":"Thromboembolism"},{"rate":null,"effect":"Hemorrhage"},{"rate":null,"effect":"Infusion-related reactions"}]},"_chembl":null,"_dailymed":null,"mechanism":{"_ai_source":"claude-haiku-4.5","explanation":"Endostar is a truncated form of human endostatin, an endogenous angiogenesis inhibitor derived from collagen XVIII. It works by suppressing vascular endothelial growth factor (VEGF)-mediated endothelial cell proliferation and migration, thereby starving tumors of their blood supply. This anti-angiogenic mechanism reduces tumor growth and metastatic potential.","oneSentence":"Endostar is a recombinant human endostatin that inhibits angiogenesis by blocking new blood vessel formation in tumors.","_ai_confidence":"medium"},"_scrapedAt":"2026-03-28T01:10:55.127Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Non-small cell lung cancer (NSCLC)"},{"name":"Other solid tumors (in development)"}]},"trialDetails":[{"nctId":"NCT06965231","phase":"PHASE2","title":"Perioperative Toripalimab and Endostatin for Stage II Melanoma: A Phase II Trial","status":"RECRUITING","sponsor":"Fudan University","startDate":"2025-01-01","conditions":"Melanoma of Skin, Acral Melanoma, Stage II Melanoma","enrollment":58},{"nctId":"NCT06618391","phase":"PHASE2","title":"Local Injection and Systemic Therapy in the Treatment of NSCLC.","status":"NOT_YET_RECRUITING","sponsor":"Henan Cancer Hospital","startDate":"2024-10-08","conditions":"Non-small Cell Lung Cancer","enrollment":84},{"nctId":"NCT05782764","phase":"PHASE4","title":"A Study of Endostar Combined With Chemotherapy and Immunotherapy in Lung Squamous Cell Carcinom","status":"UNKNOWN","sponsor":"Xuzhou Medical University","startDate":"2023-06-01","conditions":"Lung Squamous Cell Carcinoma","enrollment":30},{"nctId":"NCT04942301","phase":"PHASE1","title":"PK Study for Endostar Continuous Intravenous Infusion in NSCLC Patients With 1st-line Platinum Based Chemotherapy","status":"UNKNOWN","sponsor":"Jiangsu Simcere Pharmaceutical Co., Ltd.","startDate":"2021-07-30","conditions":"Advanced or Metastatic NSCLC","enrollment":24},{"nctId":"NCT04699214","phase":"PHASE2","title":"Endostar Combined With AI Regimen Compared With AI in Adjuvant Treatment","status":"UNKNOWN","sponsor":"Yong Chen","startDate":"2020-09-01","conditions":"Other Disorders of Soft Tissues","enrollment":210},{"nctId":"NCT04613284","phase":"PHASE4","title":"Rh-Endostatin Combined With CCRT(50 Gy) Followed by Durvalumab Maintenance for the Treatment of Specific Phase III NSCLC","status":"UNKNOWN","sponsor":"Shanghai Chest Hospital","startDate":"2020-12-01","conditions":"Lung Cancer","enrollment":97},{"nctId":"NCT04303130","phase":"PHASE2","title":"Camrelizumab Combined With Endostar for First-line Treatment in Subjects With Advanced Squamous NSCLC","status":"UNKNOWN","sponsor":"Peking University Cancer Hospital & Institute","startDate":"2019-12-31","conditions":"Non-small Cell Lung Cancer","enrollment":52},{"nctId":"NCT03932266","phase":"PHASE2","title":"Endostar Combined With Induction Chemotherapy and Concurrent Chemoradiotherapy for Locoregional Nasopharyngeal Carcinoma","status":"UNKNOWN","sponsor":"Jiangsu Cancer Institute & Hospital","startDate":"2019-06","conditions":"Nasopharyngeal Carcinoma","enrollment":73},{"nctId":"NCT03907098","phase":"PHASE2","title":"Endostar in Combination With Chemotherapy in HER-2 Negative Advanced Breast Cancer","status":"UNKNOWN","sponsor":"Zhejiang Cancer Hospital","startDate":"2016-06-30","conditions":"Breast Cancer","enrollment":50},{"nctId":"NCT03706703","phase":"PHASE2","title":"Rh-Endostatin (Endostar®) Continuous Intravenous Infusion","status":"UNKNOWN","sponsor":"Affiliated Cancer Hospital & Institute of Guangzhou Medical University","startDate":"2018-10-01","conditions":"Lung Cancer","enrollment":50},{"nctId":"NCT02590133","phase":"PHASE2","title":"A Phase II Clinical Trial of Chemotherapy With or Without Endostar® Continuous Intravenous Infusion in Refractory NPC","status":"UNKNOWN","sponsor":"Yun-fei Xia","startDate":"2015-07","conditions":"Nasopharyngeal Carcinoma","enrollment":328},{"nctId":"NCT03095079","phase":"PHASE2","title":"Rh-endostatin in Combination With Dacarbazine and Cisplatin as the First Line Therapy for Metastatic Melanoma","status":"UNKNOWN","sponsor":"Peking University Cancer Hospital & Institute","startDate":"2016-10","conditions":"Melanoma","enrollment":70},{"nctId":"NCT02283476","phase":"PHASE3","title":"The Comparative Study on Rh-Endostatin (Endostar®) Continuous Intravenous Infusion and Routine i.v in Combination With GP Regimens for Phase III B/IV Squamous Cell Lung Cancer and Biological Markers Exploration.","status":"UNKNOWN","sponsor":"Jiangsu Simcere Pharmaceutical Co., Ltd.","startDate":"2014-11","conditions":"Lung Cancer","enrollment":200},{"nctId":"NCT01531790","phase":"PHASE1","title":"A Study of Continuous Endostar Intravenous Infusion Combined With Pemetrexed and Carboplatin in Advanced Non Small Cell Lung Cancer Patients","status":"COMPLETED","sponsor":"Jiangsu Simcere Pharmaceutical Co., Ltd.","startDate":"2011-09","conditions":"Non-Small Cell Lung Cancer","enrollment":19}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":2,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":[],"phase":"phase_3","status":"active","brandName":"Endostar continuous intravenous infusion","genericName":"Endostar continuous intravenous infusion","companyName":"Jiangsu Simcere Pharmaceutical Co., Ltd.","companyId":"jiangsu-simcere-pharmaceutical-co-ltd","modality":"Small molecule","firstApprovalDate":"","aiSummary":"Endostar is a recombinant human endostatin that inhibits angiogenesis by blocking new blood vessel formation in tumors. Used for Non-small cell lung cancer (NSCLC), Other solid tumors (in development).","enrichmentLevel":3,"visitCount":1,"trialStats":{"total":0,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}